ALNY

AI Memo

Alnylam

As of 2026-08-08/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-08-08 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

—

Key catalyst

AMVUTTRA China commercialization path • 2026-11-06

Base target: $255 / p=50% prob

Biggest risk

The guidance reduction signals a slower ATTR-CM volume ramp than previously expected. Pfizer’s VYNDAQEL/VYNDAMAX and BridgeBio’s ATTRUBY are approved oral competitors, while clinical, regulatory, and China authorization outcomes remain uncertain. Secondary packet coverage reports a sharp post-print decline, and analyst revision data are unavailable.

Invalidation

Break below $175 or thesis failure.

What would change my mind?

AMVUTTRA demand and TTR franchise growth remain powerful, with quarterly TTR revenue above $1 billion, expanding ATTR-CM opportunity, a China commercialization option, and a dated ALN-HTT02 clinical readout. [#SEC-8K-2026-07-30]

Research note

Recommendation

—

Confidence

medium

As of

2026-08-08

Base target

$255

p=50%

Bull target

$330

p=25%

Bear target

$175

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Post-earnings guidance reset digestion
ALN-HTT02 Phase 1 results at EHDN
AMVUTTRA demand and TTR franchise growth remain powerful, with quarterly TTR revenue above $1 billion, expanding ATTR-CM opportunity, a China commercialization option, and a dated ALN-HTT02 clinical readout.

BearKey bullets

ALN-HTT02 clinical results, other pipeline readouts, and regulatory outcomes could disappoint or be delayed.
AMVUTTRA China commercialization is contingent on marketing authorization, with timing unavailable.
ATTR-CM diagnosis, access, prescriber expansion, and launch execution may progress more slowly than expected.

WatchKey bullets

AMVUTTRA China commercialization path

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $255 (p=50%)

Target spread vs base: +29% / -31%

Scenario probabilities

Bull Target: $330 (p=25%)Base Target: $255 (p=50%)Bear Target: $175 (p=25%)

Commentary

News tone is negative after the earnings-related guidance cut and sharp reported share-price decline, despite strong reported product growth. Social coverage is unavailable. The dated EHDN catalyst improves forward specificity, but missing analyst revisions and target-count data reduce confidence in the valuation signal.

As of 2026-08-08 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Post-earnings guidance reset digestion
ALN-HTT02 Phase 1 results at EHDN

Scenarios

Bull Target (Scenario probability)

$330 / p=25% prob

Base Target (Scenario probability)

$255 / p=50% prob

Bear Target (Scenario probability)

$175 / p=25% prob

Analysis 2026-08-08 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

-0.55

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-11-06
AMVUTTRA China commercialization path
Alnylam entered an exclusive agreement with BeOne Medicines for AMVUTTRA commercialization and distribution in Mainland China and Macau, subject to marketing authorization. Timing and approval probability remain unspecified. [#SEC-8K-2026-07-30]
Prob 45.00% • Move 10.00% • Priced-in 35.00%

Short-term Catalysts

Next few weeks

Post-earnings guidance reset digestion
2026-11-06
Q2 global net product revenue reached $1.172 billion, but management reduced full-year 2026 TTR revenue guidance from $4.4-$4.7 billion to $4.2-$4.5 billion, citing normalization of second-line ATTR-CM volume. This may keep near-term sentiment volatile despite strong underlying growth. [#SEC-8K-2026-07-30]
Prob 70% • Move -10% • Priced-in 75%

Long-term Catalysts

Months to a year

ALN-HTT02 Phase 1 results at EHDN
2026-10-23
The company stated that initial results from the Phase 1 ALN-HTT02 trial in Huntington’s disease would be presented at EHDN. The EHDN Clinical Research Congress is scheduled for October 22-24, 2026; the readout remains clinically and commercially uncertain. [#SEC-8K-2026-07-30]
Prob 55% • Move 14% • Priced-in 35%

Risks

ALN-HTT02 clinical results, other pipeline readouts, and regulatory outcomes could disappoint or be delayed.
AMVUTTRA China commercialization is contingent on marketing authorization, with timing unavailable.
ATTR-CM diagnosis, access, prescriber expansion, and launch execution may progress more slowly than expected.
Analyst target count, revisions, and estimate-change data are unavailable, limiting valuation confirmation.
Pfizer’s VYNDAQEL/VYNDAMAX and BridgeBio’s ATTRUBY compete directly in ATTR-CM and are oral products with lower list prices identified in Alnylam’s 10-K. [#10-K-2026-02-12]
Reduced 2026 TTR guidance and normalization of second-line ATTR-CM demand.

Peers

Symbol	Summary
PFE	Direct ATTR-CM operating comparator: Pfizer markets oral VYNDAQEL/VYNDAMAX (tafamidis), an approved ATTR-CM therapy that Alnylam identifies as a competing product. [#10-K-2026-02-12]
BBIO	Direct ATTR-CM operating comparator: BridgeBio markets oral ATTRUBY (acoramidis), another approved ATTR-CM therapy identified by Alnylam as a competitor. [#10-K-2026-02-12]
IONS	Direct RNA therapeutics and ATTR comparator: Ionis markets WAINUA with AstraZeneca for hATTR-PN and is developing an ATTR-CM candidate, according to Alnylam’s 10-K. [#10-K-2026-02-12]

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-08-08

Loading AI feed…

Symbol

Summary

PFE

Direct ATTR-CM operating comparator: Pfizer markets oral VYNDAQEL/VYNDAMAX (tafamidis), an approved ATTR-CM therapy that Alnylam identifies as a competing product. [#10-K-2026-02-12]

BBIO

Direct ATTR-CM operating comparator: BridgeBio markets oral ATTRUBY (acoramidis), another approved ATTR-CM therapy identified by Alnylam as a competitor. [#10-K-2026-02-12]

IONS

Direct RNA therapeutics and ATTR comparator: Ionis markets WAINUA with AstraZeneca for hATTR-PN and is developing an ATTR-CM candidate, according to Alnylam’s 10-K. [#10-K-2026-02-12]